{
    "id": "b0558bc9-1b40-4588-b7cc-e46176c0ac4e",
    "indications": {
        "text": "ondansetron orally disintegrating tablets indicated prevention nausea vomiting associated : highly emetogenic cancer chemotherapy , including cisplatin greater equal 50 mg/m2 initial repeat courses moderately emetogenic cancer chemotherapy radiotherapy patients receiving either total body irradiation , single high-dose fraction abdomen , daily fractions abdomen ondansetron orally disintegrating tablets also indicated prevention postoperative nausea and/or vomiting .",
        "doid_entities": [
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "full prescribing information recommended adults pediatrics . ( 2 ) patients severe hepatic impairment : exceed total daily dose 8 mg. ( 2.2 , 8.6 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "product : 50090-1128 ndc : 50090-1128-0 4 tablet , orally disintegrating blister pack / 1 carton ndc : 50090-1128-1 30 tablet , orally disintegrating blister pack / 1 carton ndc : 50090-1128-2 10 tablet , orally disintegrating blister pack / 1 carton ndc : 50090-1128-3 10 tablet , orally disintegrating blister pack / 2 carton product : 50090-1200 ndc : 50090-1200-0 10 tablet , orally disintegrating blister pack / 1 carton ndc : 50090-1200-1 20 tablet , orally disintegrating blister pack / 1 carton ndc : 50090-1200-2 5 tablet , orally disintegrating blister pack / 1 carton ndc : 50090-1200-3 10 tablet , orally disintegrating blister pack / 3 carton",
    "adverseReactions": "ondansetron orally disintegrating tablets contraindicated patients : known hypersensitivity ( e.g . , anaphylaxis ) ondansetron components formulation [ ( 6.2 ) ] receiving concomitant apomorphine due risk profound hypotension loss consciousness",
    "ingredients": [
        {
            "name": "ONDANSETRON",
            "code": "4AF302ESOS",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7773"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2877"
        },
        {
            "name": "SILICA",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        }
    ],
    "organization": "A-S Medication Solutions",
    "name": "Ondansetron",
    "effectiveTime": "20250515",
    "indications_original": "Ondansetron orally disintegrating tablets are indicated for the prevention of nausea and vomiting associated with:\n                  \n                     highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2\n                     \n                     initial and repeat courses of moderately emetogenic cancer chemotherapy\n                     radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen\u00a0\u00a0\u00a0 \n                  \n                  Ondansetron orally disintegrating tablets also indicated for the prevention of postoperative nausea and/or vomiting.",
    "contraindications_original": "See full prescribing information for the recommended dosage in adults and pediatrics. (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg. ( 2.2 , 8.6 )",
    "warningsAndPrecautions_original": "Product:    50090-1128\n                  NDC:    50090-1128-0   4 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1128-1   30 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1128-2   10 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1128-3   10 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  2  in a  CARTON \n                  Product:    50090-1200\n                  NDC:    50090-1200-0   10 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1200-1   20 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1200-2   5 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1200-3   10 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  3  in a  CARTON",
    "adverseReactions_original": "Ondansetron orally disintegrating tablets are contraindicated in patients:\n                  \n                     known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation [see Adverse Reactions (6.2)]\n                     \n                     receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness",
    "drug": [
        {
            "name": "Ondansetron",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7773"
        }
    ]
}